{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:07Z","timestamp":1792799407596,"version":"4.5.0"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["P01CA244118"],"award-info":[{"award-number":["P01CA244118"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["K08 CA241088"],"award-info":[{"award-number":["K08 CA241088"]}]},{"name":"Cancer Research Institute","id":[{"id":"https:\/\/ror.org\/02f3xk561","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019319","name":"Ressler Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,23]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311). The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Six patients were enrolled, 4 having relapses after prior neoadjuvant chemotherapy and 2 who were previously untreated. Toxicities included 1 patient having grade 3 hypotension and type 1 diabetes mellitus, 3 patients with hypothyroidism, and all patients having constitutional symptoms known to be associated with the administration of T-VEC. One patient had a pathologic complete response, 3 patients had pathologic partial responses, 1 showed no significant response, and 1 had disease progression. Biopsies demonstrated increased immune cell infiltration in samples from patients who responded to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0145","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T09:24:54Z","timestamp":1690449894000},"page":"1628-1637","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-3628","authenticated-orcid":true,"given":"Vina P.","family":"Nguyen","sequence":"first","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":true,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-6137","authenticated-orcid":true,"given":"Theodore S.","family":"Nowicki","sequence":"additional","affiliation":[{"name":"2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California."},{"name":"3Parker Institute for Cancer Immunotherapy, San Francisco, California."},{"name":"4Department of Pediatrics, Division of Pediatric Hematology\/Oncology, University of California, Los Angeles, Los Angeles, California."},{"name":"5Department of Microbiology, Immunology and Genetics, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8001-6235","authenticated-orcid":true,"given":"Nila","family":"Elumalai","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-5329","authenticated-orcid":true,"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-4690","authenticated-orcid":true,"given":"Ignacio","family":"Baselga-Carretero","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-292X","authenticated-orcid":true,"given":"Maggie L.","family":"DiNome","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-4499","authenticated-orcid":true,"given":"Helena R.","family":"Chang","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1793-1720","authenticated-orcid":true,"given":"Denise K.","family":"Oseguera","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":true,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California."},{"name":"5Department of Microbiology, Immunology and Genetics, University of California, Los Angeles, Los Angeles, California."},{"name":"6Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California."},{"name":"7Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-9076","authenticated-orcid":true,"given":"John A.","family":"Glaspy","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"2023082314064772300_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"2023082314064772300_bib2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023082314064772300_bib3","doi-asserted-by":"crossref","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"2023082314064772300_bib4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"2023082314064772300_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"2023082314064772300_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembro-lizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in patients with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023082314064772300_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase Ib open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann Oncol"},{"key":"2023082314064772300_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388(9)","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilumumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib14","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023082314064772300_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review","volume":"11","author":"Planes-Laine","year":"2019","journal-title":"Cancer"},{"key":"2023082314064772300_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"2023082314064772300_bib17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple negative breast cancer: impassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"2023082314064772300_bib18","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.18632\/oncotarget.26893","article-title":"Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer","volume":"10","author":"Jiang","year":"2019","journal-title":"Oncotarget"},{"key":"2023082314064772300_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","article-title":"Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies","volume":"191","author":"Torres","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2023082314064772300_bib20","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023082314064772300_bib21","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023082314064772300_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023082314064772300_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"2023082314064772300_bib24","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2023082314064772300_bib26","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2023082314064772300_bib27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2023082314064772300_bib28","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2023082314064772300_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","article-title":"SomaticSniper: identification of somatic point mutations in whole genome sequencing data","volume":"28","author":"Larson","year":"2012","journal-title":"Bioinformatics"},{"key":"2023082314064772300_bib30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41588-018-0257-y","article-title":"A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data","volume":"50","author":"Ainscough","year":"2018","journal-title":"Nat Genet"},{"key":"2023082314064772300_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2023082314064772300_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nbt.3122","article-title":"StringTie enables improved reconstruction of a transcriptome from RNA-seq reads","volume":"33","author":"Pertea","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2023082314064772300_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2023082314064772300_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2023082314064772300_bib35","first-page":"S808","article-title":"Abstract LBA13 \u2013 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial","volume":"33","author":"Kok","year":"2022","journal-title":"Ann Oncol"},{"key":"2023082314064772300_bib36","doi-asserted-by":"crossref","article-title":"Nimbus: a phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated HER2-negative metastatic breast cancer (MBC) [abstract]","author":"Barroso-Sousa","DOI":"10.1158\/1538-7445.SABCS21-GS2-10"},{"key":"2023082314064772300_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0145\/3351105\/crc-23-0145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1628\/3358380\/crc-23-0145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1628\/3358380\/crc-23-0145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:29:30Z","timestamp":1692786570000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/8\/1628\/728578\/A-Pilot-Study-of-Neoadjuvant-Nivolumab-Ipilimumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,23]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0145","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.24018727.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6762524","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018724.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018697.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791817.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791802.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791811.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791820.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791814.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6762524.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791802","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018730.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6762524.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791817","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791805","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791808.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791805.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018706.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018703.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018700.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018721.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018709.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018712.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791808","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018715.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018718.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018697","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24018706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791808","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018715.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018718.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791808.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791820.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791817.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791814.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018721.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791802.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018730.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791811.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791805.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018727.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018724.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791802","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018712.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018697.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018709.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018706.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018703.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018700.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791817","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24018727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23791805","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}